<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318419</url>
  </required_header>
  <id_info>
    <org_study_id>ALL-2017</org_study_id>
    <nct_id>NCT03318419</nct_id>
  </id_info>
  <brief_title>Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Efficacy and Safety of Cladribine in Combination With G-CSF, Low-dose Cytarabine and Pegaspargase in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia: a Phase 2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The vast majority of patients with ALL will die of the disease, and no standard chemotherapy
      regimen were defined for patients with relapsed/refractory ALL.Our previous experience has
      shown that Cladribine in combination of GAP (G-CSF priming, low dose cytarabine, and
      Pegaspargase) are effective with tolerable toxicity profiling.Thus, this phase 2 clincial
      trial is going to evaluate the efficacy and safety of cladribine in combination with G-CSF,
      low-dose cytarabine and Pegaspargase (C-GAP) in patients with refractory/relapsed acute
      Lymphoblastic Leukemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ALL is common in the elderly patients, who can not tolerate the intensified treatments. The
      vast majority of patients with ALL will die of the disease, and no standard chemotherapy
      regimen were defined for patients with relapsed/refractory ALL. Our previous experience has
      shown that Cladribine in combination of GAP(G-CSF priming, low dose cytarabine, and
      Pegaspargase) are effective with tolerable toxicity profiling.Thus, this phase 2 clincial
      trial is going to evaluate the efficacy and safety of cladribine in combination with G-CSF,
      low-dose cytarabine and aclarubicin (C-CAG) in patients with refractory/relapsed acute
      myeloid leukemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR rate</measure>
    <time_frame>Bone marrow aspiration will be done within 2 weeks after blood cell count recovery (about 4 weeks after initiation of C-GAP treatment</time_frame>
    <description>Complete Remission: less than 5% blasts in bone marrow</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Cladribine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cladribine in combination of GAP (G-CSF priming, low dose cytarabine, and Pegaspargase) will be administrated in this arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>5mg/㎡ d1-5</description>
    <arm_group_label>Cladribine group</arm_group_label>
    <other_name>cladribine injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>300ug d0-14</description>
    <arm_group_label>Cladribine group</arm_group_label>
    <other_name>granulocyte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>10mg/㎡ q12h SC d1-14</description>
    <arm_group_label>Cladribine group</arm_group_label>
    <other_name>Ara-C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>2500U/m2 im d1</description>
    <arm_group_label>Cladribine group</arm_group_label>
    <other_name>Pegaspargase injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women;

          -  Clinical diagnosis of Relapsed/Refractory ALL;

          -  ECOG performance status (PS) score 0-3;

          -  AST and ALT &lt;=2.5 times the institutional ULN;

          -  Total bilirubin &lt;=2.0 times the institutional ULN

          -  Serum creatinine&lt;2.0 times the institutional ULN;

          -  Subjects should take effective contraceptive measures，and serum or urine pregnancy
             tests must be negative during the screening and study periods in women subjects;

          -  Patients should understand the disease and voluntarily receive the study regimen and
             follow-up.

        Exclusion Criteria:

          -  Concurrent diagnosis of tumors other than ALL, with exclusion of superficial bladder
             cancer, basal cell and squamous cell carcinoma, cervical intraepithelial neoplasms
             (CIN), prostatic intraepithelial neoplasms(PIN);

          -  Active viral or bacterial infection that would impair the ability of the subject to
             receive protocol therapy;

          -  Concurrent autoimmune hemolytic anemia or immune thrombocytopenia;

          -  Subjects suffered from AIDS，active hepatitis B or C virus infection;

          -  Dementia or altered mental status that would prohibit the understanding or rendering
             of informed consent;

          -  Be allergic to any component of C-GAP regimen;

          -  Subjects ever exposed to cladribine or CAG-based regimen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yue lv, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>sun-yat sun university cancer center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hua wang, MD.</last_name>
    <email>wanghua@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yue lu, MD.</last_name>
      <phone>0086-02087342438</phone>
      <email>dr_luyue@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>dr. luyue</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

